KR890000105A - 개의 관상 비루스 왁진 - Google Patents

개의 관상 비루스 왁진 Download PDF

Info

Publication number
KR890000105A
KR890000105A KR1019880006816A KR880006816A KR890000105A KR 890000105 A KR890000105 A KR 890000105A KR 1019880006816 A KR1019880006816 A KR 1019880006816A KR 880006816 A KR880006816 A KR 880006816A KR 890000105 A KR890000105 A KR 890000105A
Authority
KR
South Korea
Prior art keywords
wax
ccv
cell
peproma
protein
Prior art date
Application number
KR1019880006816A
Other languages
English (en)
Other versions
KR970000233B1 (ko
Inventor
앨론조 길 미카엘
월리엄 마이 스테펜
Original Assignee
스투어트 알. 수터
노르덴 레보러토리스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스투어트 알. 수터, 노르덴 레보러토리스, 인크. filed Critical 스투어트 알. 수터
Publication of KR890000105A publication Critical patent/KR890000105A/ko
Application granted granted Critical
Publication of KR970000233B1 publication Critical patent/KR970000233B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/818—Viral vaccine for canidae or mustelidae, e.g. dogs, foxes, minks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

개의 관상 비루스 왁진
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 개의 관상 비루스(CCV)의 감염으로 말미암는 병으로부터 개와 같은 동물들을 보호하기 위한, 효과적인 양의 세포-관련된 CCV 페프로마 단백질로 이루어지는 왁진.
  2. 제1항에서, CCV로 감염된 세포 배양으로부터 제조되는 왁진.
  3. 제2항에서, 감염된 세포배양이 성장하는 동안 구체화된 세포의 비루스가 사실상 없는 왁진.
  4. 제1,2 또는 3항에서 보조약을 더 포함하는 왁진.
  5. 개의 관상비루스(CCV)의 감염으로 말미암는 병으로부터 동물들을 보호하기 위한 왁진을 생산하는 다음의 a. 세포배양을 최소한 0.2의 CCV로 중복감염(MOI)시키고; b. 6-18시간 동안 세포를 배양하고; c. 소모된 액체 배지를 버리고; d. 세포를 분쇄하고; e. 분쇄된 세포로부터 세포-관련된 페프로마 단백질을 수거하고; f. 세포-관련된 페프로마를 비경구적으로 허용되는 담체와 결합하는 것으로 이루어지는 방법.
  6. 제5항에서, 세포를 비경구적으로 허용되는 액체에서 분쇄하여 (e) 단계와 (f) 단계를 결합하는 방법.
  7. 제5항이나 제6항에서, 세포-관련된 페프로마 단백질을 포함하는 담체와 보조약을 혼합하는 것으로 이루어지는 방법.
  8. CCV의 감염으로 말미암는 병과 하나 또는 그 이상의 부가적인 병원체나 비루스의 감염으로 말미암는 병으로부터 개와 같은 동물을 보호하기 위한, 효과적인 양의 세포-관련된 페프로마 단백질과 하나 또는 그 이상의 부가적인 병원체나 비루스로부터 보호하는 항원제의 효과적인 양으로 이루어지는 왁진.
  9. 제8항서, 세포-관련된 페프로마 단백질이 CCV로 감염된 세포의 배양으로부터 제조되는 왁진.
  10. 제9항에서, 세포-관련된 페프로마 단백질이 성장하는 동안 생성된 세포의 CCV가 사실상 없는 왁진.
  11. 제8,9 또는 10항에서, 부가 병원체가 개의 파르보비루스(CPV)이고 부가 항원 성분이 약화된 CPV 또는 변형되어 활성화된 CPV의 효과적인 양인 왁진.
  12. 제1,2,3 또는 4항의 왁진을 동물에게 비경구적으로 투여하는 것으로 이루어지는 CCV의 감염으로 말미암는 병으로부터 개와 같은 동물을 보호하는 방법.
  13. 제8,9 또는 10항의 왁진을 동물에게 비경구적으로 투여하는 것으로 이루어지는, CCV의 감염으로 말미암는 병과 하나 또는 그 이상의 부가 병원체나 비루스의 감염으로 말미암는 병으로부터 개와 같은 동물을 보호하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880006816A 1987-06-08 1988-06-08 개과 코로나비루스 백신 KR970000233B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/059,437 US4904468A (en) 1987-06-08 1987-06-08 Canine coronavirus vaccine
US059,437 1987-06-08
US59437 1987-06-08

Publications (2)

Publication Number Publication Date
KR890000105A true KR890000105A (ko) 1989-03-11
KR970000233B1 KR970000233B1 (ko) 1997-01-08

Family

ID=22022943

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880006816A KR970000233B1 (ko) 1987-06-08 1988-06-08 개과 코로나비루스 백신

Country Status (20)

Country Link
US (1) US4904468A (ko)
EP (1) EP0295057B1 (ko)
JP (1) JP2655876B2 (ko)
KR (1) KR970000233B1 (ko)
AT (1) ATE91902T1 (ko)
AU (1) AU612151B2 (ko)
CA (1) CA1337267C (ko)
DE (1) DE3882599T2 (ko)
DK (1) DK175410B1 (ko)
ES (1) ES2058283T3 (ko)
FI (1) FI87531C (ko)
HU (1) HU203984B (ko)
IE (1) IE63006B1 (ko)
IL (1) IL86635A0 (ko)
MY (1) MY103575A (ko)
NO (1) NO176004C (ko)
NZ (1) NZ224865A (ko)
PH (1) PH27018A (ko)
PT (1) PT87668B (ko)
ZA (1) ZA884040B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5911999A (en) * 1987-09-28 1999-06-15 Pfizer, Inc. Vaccine based on TGEV for protection of dogs against canine coronavirus
ZA903142B (en) * 1989-05-03 1991-02-27 Akzo Nv Canine corona virus vaccine
US5672350A (en) * 1989-08-22 1997-09-30 Veterinary Infectious Disease Organization Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines
US5882649A (en) * 1990-04-24 1999-03-16 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
DK0528859T3 (da) * 1990-04-24 1998-09-14 Flustat Pty Ltd Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
US6372224B1 (en) 1990-11-14 2002-04-16 Pfizer Inc. Canine coronavirus S gene and uses therefor
NZ240558A (en) 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
US6057436A (en) * 1990-11-14 2000-05-02 Pfizer Inc. Canine coronavirus S gene and uses therefor
ATE256746T1 (de) * 1991-04-25 2004-01-15 Akzo Nobel Nv Subeinheits-impfstoff gegen hundecoronavirus
EP0524672A1 (en) * 1991-06-27 1993-01-27 Duphar International Research B.V CCV vaccine
US20040063093A1 (en) * 1992-04-08 2004-04-01 Pfizer, Inc. Recombinant feline coronavirus S proteins
JP3245169B2 (ja) * 1992-05-08 2002-01-07 ファイザー・インコーポレイテッド イヌ・コロナウイルスｓ遺伝子およびその使用
US5750112A (en) * 1993-02-26 1998-05-12 Solvay Animal Health, Inc. Canine coronavirus vaccine from feline enteric coronavirus
EP1780216B1 (en) * 2005-10-26 2010-12-29 Canio Buonavoglia Pantropic canine coronavirus
US7761389B2 (en) 2007-08-23 2010-07-20 Gm Global Technology Operations, Inc. Method for anomaly prediction of battery parasitic load
RU2015113826A (ru) * 2009-10-14 2015-09-20 Дзе Борд Оф Риджентс Фор Оклахома Стейт Юниверсити Выделение вируса, родственного парвовирусу-2 собак, от енота
SG11201503854UA (en) 2012-11-22 2015-06-29 Asahi Kasei Medical Co Ltd Method for producing parvovirus having high infectivity titer
CN106290880B (zh) * 2015-05-27 2019-01-04 江苏雷森生物科技有限公司 一种用于犬冠状病毒的免疫层析用试剂组合物及检测方法
EP3372677B8 (en) 2015-11-06 2019-09-25 Asahi Kasei Medical Co., Ltd. Method for producing parvovirus having high infectivity titer and high purity
CN110903387A (zh) * 2019-12-17 2020-03-24 吉林省纽卓莱生物科技有限责任公司 一种犬冠状病毒免疫球蛋白F(ab′)2及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4567043A (en) * 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
EP0218625B1 (en) * 1985-03-29 1995-04-05 Btg International Limited Infectious bronchitis virus spike protein

Also Published As

Publication number Publication date
HUT46858A (en) 1988-12-28
IL86635A0 (en) 1988-11-30
EP0295057B1 (en) 1993-07-28
FI882689A0 (fi) 1988-06-07
NO176004C (no) 1995-01-18
FI87531C (fi) 1993-01-25
KR970000233B1 (ko) 1997-01-08
MY103575A (en) 1993-08-28
NO176004B (no) 1994-10-10
NO882500L (no) 1988-12-09
DK301588D0 (da) 1988-06-02
ES2058283T3 (es) 1994-11-01
EP0295057A2 (en) 1988-12-14
PT87668B (pt) 1992-09-30
HU203984B (en) 1991-11-28
DE3882599T2 (de) 1994-02-10
JP2655876B2 (ja) 1997-09-24
FI882689A (fi) 1988-12-09
NO882500D0 (no) 1988-06-07
IE881689L (en) 1988-12-08
DK301588A (da) 1988-12-09
PH27018A (en) 1993-02-01
EP0295057A3 (en) 1989-12-27
IE63006B1 (en) 1995-03-22
PT87668A (pt) 1988-07-01
ZA884040B (en) 1989-09-27
AU1747688A (en) 1988-12-08
AU612151B2 (en) 1991-07-04
DE3882599D1 (de) 1993-09-02
US4904468A (en) 1990-02-27
ATE91902T1 (de) 1993-08-15
FI87531B (fi) 1992-10-15
NZ224865A (en) 1990-12-21
JPS63316739A (ja) 1988-12-26
CA1337267C (en) 1995-10-10
DK175410B1 (da) 2004-09-27

Similar Documents

Publication Publication Date Title
KR890000105A (ko) 개의 관상 비루스 왁진
Madin et al. Isolation of the infectious bovine rhinotracheitis virus
Carmichael et al. Anatoxins from clones of Anabaena flos-aquae isolated from lakes of western Canada: With 3 figures and 2 tables in the text
Dorson et al. The influence of fish age and water temperature on mortalities of rainbow trout, Salmo gairdneri Richardson, caused by a European strain of infectious pancreatic necrosis virus
Anjum Experimental transmission of hydropericardium syndrome and protection against it in commercial broiler chickens
Denton et al. The prevalence of Cryptococcus neoformans in various natural habitats
Sivasankar et al. Characterization of a virulent ranavirus isolated from marine ornamental fish in India
Gay et al. An aged host promotes the evolution of avirulent coxsackievirus into a virulent strain
Bieber et al. Lymphoma in cardiac transplant recipients associated with cyclosporin A, prednisone and anti-thymocyte globulin (ATG)
Dow et al. Age, strain and sex differences in susceptibility to Cysticercus fasciolaris in the mouse
Bemrick et al. Potential vectors of Dirofilaria immitis in the Brisbane area of Queensland, Australia
Jupp et al. Quantitative experiments on the vector capability of Culex (Culex) pipiens fatigans Wiedemann with West Nile and Sindbis viruses
Barnicot et al. Evidence for a second haemoglobin α-locus duplication in Macaca irus
Riley Synergism between a lactate dehydrogenase-elevating virus and Eperythrozoon coccoides
DE1950774A1 (de) Heteroploide Zellinien
DZ1550A1 (fr) Vaccin depourvu de cellules contre le virus de la maladie marek.
Larson et al. Transmission of rabbit papillomatosis by the rabbit tick, Haemaphysalis leporis palustris
Parnell et al. Predaceous fungi: a possible method of biological control of parasitic nematodes
AU597709B2 (en) Vaccines for fowl colibacillosis
KR890014127A (ko) 생 조합 백신
Wertheimer et al. Differences in susceptibility among three stocks of chinook salmon, Oncorhynchus tshawytscha, to two isolates of infectious hematopoietic necrosis virus
Strong Effect of Removal of the Frontal Ganglion on Corpus Allatum Function in Locusta migratoria migratorioides R. & F.
Okuno et al. Experimental transmission of Japanese encephalitis virus by Culex tritaeniorhynchus and C. fuscocephalus
KR900017611A (ko) 개의 코로나 바이러스 백신
US4004974A (en) Live virus culture vaccine against carnivore distemper and method of producing same

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20051230

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee